Efficacy of nonsurgical septal reduction therapy in symptomatic patients with obstructive hypertrophic cardiomyopathy and provocable gradients

被引:24
作者
Lakkis, N [1 ]
Plana, JC [1 ]
Nagueh, S [1 ]
Killip, D [1 ]
Roberts, R [1 ]
Spencer, WH [1 ]
机构
[1] Baylor Coll Med, Dept Internal Med, Cardiol Sect, Houston, TX 77030 USA
关键词
D O I
10.1016/S0002-9149(01)01748-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The hemodynamic burden caused by left ventricular obstruction along with impaired systolic and diastolic function explains the disabling symptoms of heart failure that are common in patients with obstructive hypertrophic cardiomyopathy (HC).(1) Relief of the outflow obstruction is the cornerstone of the successful treatment of this disease.(2) Medical therapy with negative inotropic medications like beta blockers, calcium antagonists, and disopyramide are the first line of treatment.(3,4) Many patients, however, continue to experience symptoms despite optimal medical therapy. These patients are left with 3 options: myotomymyomectomy,(5-7) dual-chamber pacing,(8-12) or nonsurgical septal reduction.(13-20) In this report, we share our experience with nonsurgical septal reduction in symptomatic patients with low resting gradients (< 30 mm Hg), and significant (> 60 mm Hg) provocable gradients after the infusion of low-dose dobutamine.
引用
收藏
页码:583 / +
页数:5
相关论文
共 20 条
  • [1] LONG-TERM FOLLOW-UP OF PATIENTS UNDERGOING MYOTOMY MYECTOMY FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY
    COHN, LH
    TREHAN, H
    COLLINS, JJ
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 1992, 70 (06) : 657 - 660
  • [2] Erwin JP, 2000, MAYO CLIN PROC, V75, P173
  • [3] Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients
    Faber, L
    Meissner, A
    Ziemssen, P
    Seggewiss, H
    [J]. HEART, 2000, 83 (03) : 326 - 331
  • [4] Fananapazir L, 1998, J AM COLL CARDIOL, V31, P259
  • [5] IMPACT OF DUAL-CHAMBER PERMANENT PACING IN PATIENTS WITH OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY WITH SYMPTOMS REFRACTORY TO VERAPAMIL AND BETA-ADRENERGIC BLOCKER THERAPY
    FANANAPAZIR, L
    CANNON, RO
    TRIPODI, D
    PANZA, JA
    [J]. CIRCULATION, 1992, 85 (06) : 2149 - 2161
  • [6] Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy - Outcome in the first series of patients
    Knight, C
    Kurbaan, AS
    Seggewiss, H
    Henein, M
    Gunning, M
    Harrington, D
    Fassbender, D
    Gleichmann, U
    Sigwart, U
    [J]. CIRCULATION, 1997, 95 (08) : 2075 - 2081
  • [7] Five years of percutaneous transluminal septal myocardial ablation
    Knight, CJ
    [J]. HEART, 2000, 83 (03) : 255 - 256
  • [8] Nonsurgical septal reduction for symptomatic hypertrophic obstructive cardiomyopathy: The Baylor experience (1996-1999)
    Lakkis, N
    Nagueh, S
    Killip, D
    Torre, G
    Roberts, R
    Spencer, W
    [J]. JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2000, 13 (03) : 157 - 159
  • [9] Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy
    Lakkis, NM
    Nagueh, SF
    Kleiman, NS
    Killip, D
    He, ZX
    Verani, MS
    Roberts, R
    Spencer, WH
    [J]. CIRCULATION, 1998, 98 (17) : 1750 - 1755
  • [10] Nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy: One-year follow-up
    Lakkis, NM
    Nagueh, SF
    Dunn, JK
    Killip, D
    Spencer, WH
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (03) : 852 - 855